Tango Therapeutics (TNGX) Invested Capital (2020 - 2026)

Tango Therapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $391.5 million for Q1 2026.

• In Q1 2026, Invested Capital rose 134.78% year-over-year to $391.5 million; the TTM figure through Mar 2026 stood at $391.5 million (up 134.78% YoY), while the FY2025 annual figure was $346.2 million, up 73.51% from the prior year.
• Invested Capital was $391.5 million for Q1 2026 at Tango Therapeutics, up from $346.2 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $391.5 million in Q1 2026 to a low of $135.0 million in Q2 2025.
• Historically, Invested Capital has averaged $250.1 million across 5 years, with a median of $249.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Invested Capital surged 453.38% in 2022, then sank 45.51% in 2025.
• A 5-year view of Invested Capital shows it stood at $249.5 million in 2022, then increased by 1.46% to $253.1 million in 2023, then retreated by 21.17% to $199.5 million in 2024, then surged by 73.51% to $346.2 million in 2025, then grew by 13.09% to $391.5 million in 2026.
• The last three Invested Capital figures came in at $391.5 million (Q1 2026), $346.2 million (Q4 2025), and $160.0 million (Q3 2025), per Business Quant data.